The development of a cost-effective leukodepletion system for fresh whole blood is proposed that will have four important characteristics. The system will 1) provide a 4-5 log leukocyte removal efficiency, 2) allow for the recovery of at least 80-90 percent of platelets in a viable form, 3) be capable of recovering greater than 90 percent red blood cells, and 4) will reduce processing time by a factor of 5. The heart of the system will be a leukodepletion device that will be designed using a proprietary Continuous-Gradient Flow Management (CGFM) design strategy developed at Synosys, Inc. The CGFM method follows an empirically derived rational design strategy to maximize flow rate for a desired leukodepletion efficiency and leukocyte capacity. The device will be the disposable element in a leukodepletion system designed to process fresh whole blood rapidly in a safe and cost-effective manner. The ability to leukodeplete fresh whole blood with a single device will eliminate the need for individual leukodepletion steps used today for blood components, this, providing blood products of superior quality at lower cost.Proposed Commercial Application:This device would allow for the cost-effective leukodepletion of blood collected for transfusions (13 Million Units per year in the US alone).
Thesaurus Terms:biomedical equipment development, blood filtration, cell sorting, consumable /disposable biomedical equipment, leukocyte method development human tissue, tissue donor
